Significance of EGFR and c-erbB-2 Expression in Extrahepatic Bile Duct Cancer.
- Author:
Gil Soo SON
1
;
Sang Yong CHOI
;
Sung Ock SUH
;
Young Chul KIM
Author Information
1. Department of Surgery, Korea University College of Medicine, Korea.
- Publication Type:Original Article
- Keywords:
Extrahepatic bile duct cancer;
EGFR;
c-erbB-2
- MeSH:
Bile Duct Neoplasms;
Bile Ducts;
Bile Ducts, Extrahepatic*;
Epidermal Growth Factor;
Lymph Nodes;
Neoplasm Metastasis;
Prognosis;
Receptor, erbB-2
- From:Korean Journal of Hepato-Biliary-Pancreatic Surgery
1998;2(1):95-102
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Until now, surgical treatment of bile duct carcinoma has been unsatisfactory. There have been few reports dealing with the clinical significance of epidermal growth factor receptor(EGFR) and c-erbB-2 in bile duct cancer. To evaluate epidermal growth factor receptor(EGFR) and c-erbB-2 protein as a marker for prognosis, we analyzed the data and outcome of 32 cases of extrahepatic bile duct carcinoma immunohistologically, as well as clinicopathologically. The expressions of EGFR and c-erbB-2 showed in 71.9%(23/32) and 34.4%(11/32), respectively. The expression of EGFR was closely associated with the expression of c-erbB-2 (p<0.05). The expression rate of EGFR was significantly higher in well-differentiated cancer than in poorly-differentiated cancer (p<0.05), but was not related to stage, or lymph node metastasis. The expression of c-erbB-2 was not related to stage, lymph node metastasis, and differentiation. The expressions of EGFR and c-erbB-2 did not correlate with survival. In conclusion, the expression of EGFR or c-erbB-2 may be used as a tumor marker, but not as a prognostic factor in extrahepatic bile duct cancer.
